Atrial fibrillation is highly prevalent yet undertreated in patients with biopsy-proven nonalcoholic steatohepatitis.
Maureen WhitsettJane WilcoxAmy YangLihui ZhaoMary RinellaLisa B VanWagnerPublished in: Liver international : official journal of the International Association for the Study of the Liver (2018)
Atrial fibrillation prevalence is two-fold higher in patients with NASH compared to the general population. Patients with NASH have a high risk of stroke; however, many do not receive appropriate guideline-directed therapy. Future studies are needed to identify whether guideline-based management of atrial fibrillation in NASH reduces cardiovascular morbidity and mortality.